Literature DB >> 18404006

Guideline recommendations for heart complications in thalassemia major.

Tiziana Cogliandro1, Giorgio Derchi, Luigi Mancuso, M Carolina Mayer, Bruno Pannone, Alessia Pepe, Marcello Pili, Patrizio Bina, Paolo Cianciulli, Vincenzo De Sanctis, Aurelio Maggio.   

Abstract

Thalassemia major is an inherited hemoglobin disorder resulting in a chronic hemolytic anemia. Transfusion therapy together with elevated gastrointestinal absorption of iron determines iron overload, which causes most of the mortality and morbidity associated with the disease. Heart complications represent the leading cause of mortality in this disease, although, because of an improvement in chelation treatment, an important and progressive increase of life expectancy mainly as a result of a reduction in mortality due to cardiac dysfunction has been demonstrated in recent years. Clinical pictures of heart damage range from the involvement of the ventricles to pulmonary hypertension or symptomatic ventricular or supra-ventricular arrhythmias. For this reason, the possibility of having specific recommendations is noteworthy. These recommendations outline the definition, the follow-up and the treatment of the main heart complications in this group of patients. The identification of topics and the nomination of the committee were made on behalf of the Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE). The document obtained the auspices of ANMCO, SIC, SIRM and the Cardiovascular Magnetic Resonance Working Groups of the ANMCO, SIC and SIRM. All recommendations provided in this document have been performed according to the American Cardiology College (ACC) and American Heart Association (AHA) guidelines. Moreover, the recommendations were reviewed by two external referees before the definitive approval.

Entities:  

Mesh:

Year:  2008        PMID: 18404006     DOI: 10.2459/JCM.0b013e3282f20847

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  15 in total

1.  The effect of metoprolol succinate on the cardiac function of patients with thalassaemia cardiomyopathy: a double-blind randomised study.

Authors:  Javad Kojury; Abdolali Zolghadrasli; Mehran Karimi; Mohammad Ali Babaee Beighi; Soha Namazi
Journal:  Heart Asia       Date:  2014-04-17

2.  Hepatocellular carcinoma in thalassemia: A critical review.

Authors:  Andrea Mancuso
Journal:  World J Hepatol       Date:  2010-05-27

3.  Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report.

Authors:  Claudia R Morris; Hae-Young Kim; Felicia Trachtenberg; John Wood; Charles T Quinn; Nancy Sweeters; Janet L Kwiatkowski; Alexis A Thompson; Patricia J Giardina; Jeanne Boudreaux; Nancy F Olivieri; John B Porter; Ellis J Neufeld; Elliott P Vichinsky
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

4.  Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population.

Authors:  Luca Antonio Felice Di Odoardo; Marianna Giuditta; Elena Cassinerio; Alberto Roghi; Patrizia Pedrotti; Marco Vicenzi; Veronica Maria Sciumbata; Maria Domenica Cappellini; Alberto Pierini
Journal:  Intern Emerg Med       Date:  2017-04-29       Impact factor: 3.397

5.  Genotypic groups as risk factors for cardiac magnetic resonance abnormalities and complications in thalassemia major: a large, multicentre study.

Authors:  Laura Pistoia; Antonella Meloni; Paolo Ricchi; Aldo Filosa; Roberto Lisi; Aurelio Maggio; Rosamaria Rosso; Giuseppe Messina; Nicola Dello Iacono; Liana Cuccia; Saveria Campisi; Massimiliano Missere; Massimo Midiri; Antonino Vallone; Stefania Renne; Nicolò Schicchi; Riccardo Righi; Maurizio Mangione; Vincenzo Positano; Alessia Pepe
Journal:  Blood Transfus       Date:  2020-07-22       Impact factor: 3.443

6.  A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia.

Authors:  Madelyn S Hanson; Hao Xu; Timothy C Flewelen; Sandra L Holzhauer; Dawn Retherford; Deron W Jones; Anne C Frei; Kirkwood A Pritchard; Cheryl A Hillery; Neil Hogg; Nancy J Wandersee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-02       Impact factor: 4.733

Review 7.  Iron overload and arrhythmias: Influence of confounding factors.

Authors:  Yukitaka Shizukuda; Douglas R Rosing
Journal:  J Arrhythm       Date:  2019-06-20

8.  Correlation between Serum Fatty Acid Binding Protein 4 (FABP4) Levels and Cardiac Function in Patients with Thalassemia Major.

Authors:  Pandji I Fianza; Anita Rahmawati; Shofura Afifah; Suhendra Praptama; Mohammad Ghozali; Teddy A Sihite; Djatnika Setiabudi; Mas R A A Syamsunarno; Suthat Fucharoen; Ramdan Panigoro
Journal:  Dis Markers       Date:  2021-12-27       Impact factor: 3.434

Review 9.  Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area.

Authors:  Mohamad H Qari; Yasser Wali; Muneer H Albagshi; Mohammad Alshahrani; Azzah Alzahrani; Ibrahim A Alhijji; Abdulkareem Almomen; Abdullah Aljefri; Hussain H Al Saeed; Shaker Abdullah; Ahmad Al Rustumani; Khoutir Mahour; Shaker A Mousa
Journal:  Orphanet J Rare Dis       Date:  2013-09-17       Impact factor: 4.123

10.  Early detection of myocardial dysfunction in poorly treated pediatric thalassemia children and adolescents: Two Saudi centers experience.

Authors:  Mohamed H Ibrahim; Ahmed A Azab; Naglaa M Kamal; Mostafa A Salama; Soha A Ebrahim; Ashraf M Shahin; Akram E El-Sadek; Waleid E Abdulghany; Laila M Sherief; Enas A A Abdallah
Journal:  Ann Med Surg (Lond)       Date:  2016-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.